Brokerages Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $29.78

enGene Holdings Inc. (NASDAQ:ENGN) has received an average recommendation of “Buy” from the eleven analysts that are presently covering the company, MarketBeat.com reports. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $29.78.

Several brokerages have issued reports on ENGN. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 target price on shares of enGene in a research note on Monday, December 23rd. Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research note on Monday, November 18th. HC Wainwright began coverage on shares of enGene in a research note on Monday, December 23rd. They set a “buy” rating and a $25.00 target price on the stock. Finally, Raymond James initiated coverage on shares of enGene in a research note on Wednesday, November 27th. They set an “outperform” rating and a $23.00 target price on the stock.

enGene Price Performance

Shares of NASDAQ ENGN opened at $7.39 on Friday. The stock has a market capitalization of $326.76 million, a price-to-earnings ratio of -12.74 and a beta of -0.65. enGene has a 12 month low of $4.42 and a 12 month high of $18.40. The firm’s 50 day simple moving average is $7.33 and its 200-day simple moving average is $7.47. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. Analysts expect that enGene will post -1.57 EPS for the current year.

Hedge Funds Weigh In On enGene

Several institutional investors have recently modified their holdings of the business. Franklin Resources Inc. grew its stake in shares of enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after acquiring an additional 389,918 shares in the last quarter. Point72 Asset Management L.P. grew its stake in shares of enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after acquiring an additional 619,100 shares in the last quarter. Finally, Wolverine Asset Management LLC purchased a new stake in shares of enGene during the 3rd quarter worth $37,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.